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Nicotine is the psychoactive agent involved in nicotine dependence. However, nicotine as a drug, and its
effects on human psychology are largely under-investigated in genetic studies. In this study, we recruited 208
current non-smokers to evaluate the effect of nicotine and its relationship to genetic risks to nicotine
dependence. Exploratory and confirmatory factor analyses, as well as measurement invariance testing, were
conducted to evaluate the latent factor structures of the POMS, PANAS and DEN questionnaires across 3
nicotine doses. Structural models were used to examine the effects of nicotine and their relationship to
genetic risks of nicotine dependence. We found that nicotine administration led to the change of both
measurement construct and factor means, indicating the causal effect of nicotine on the psychological
responses. The genotypes of rs588765 predicted the scores of the DEN Confused and Dizzy factors (p 5
0.0003 and 0.001 respectively), and rs16969968 and rs588765 were associated with the PANAS Nervous
factor (p 5 0.006 and 0.007 respectively). Our study suggested that genetic risk of nicotine dependence is
associated with acute psychological responses. The integration of psychometric analyses and dose effects
could be a powerful approach for genetic study of nicotine dependence.
I n the last several years, genetic studies of smoking and nicotine dependence have made significant progress,exemplified by the identification of the CHRNA5-CHRNA3-CHRNB4 locus. Genetic variants at this locushave been shown to be associated with a number of smoking phenotypes such as the number of cigarettes
smoked per day1–4, nicotine dependence as defined by DSM IV5,6 and the Fagerström Test for Nicotine
Dependence7,8, age of smoking onset5,9,10 and plasma cotinine concentration11. This locus includes the
CHRNA5, CHRNA3 and CHRNB4 genes. While a non-synonymous SNP, rs16969968, in the CHRNA5 gene
has emerged as a functional candidate, it may not be the one tagging the strongest association signal12. Further
analyses reveal that there are multiple statistically independent association signals at this locus, represented by
SNPs rs16969968, rs588765 and rs57877613.
Nicotine, the primary psychoactive substance in cigarette smoke, has broad psychological effects on humans14.
When first exposed to nicotine, either by smoking or other routes of administration, some people feel pleasant
and relaxed, while others feel dizzy and nauseous. These initial responses to nicotine have significant impacts on
sustained smoking and subsequent development of nicotine dependence15–18. However, in a typical genetic study,
the psychological effects of nicotine are rarely utilized and included in association testing. This omission is due, in
part, to the fact that little is known of the relationship between these effects and genetic risks of nicotine
dependence. In the literature, there are a few reports on the association between subjective measures and genetic
variants in the nicotinic receptors, and some nominal associations are found in the CHRNB3/CHRNA619 and
CHRNB220 genes. These studies use the scores of individual items or several items that contribute to a common
factor, but these studies do not control for measurement errors and correlations between items, and do not have
nicotine dose effect information.
Psychometric analysis with structural equation modeling provides a framework for constructing latent factor
structures that can take into account measurement errors, item residual correlations and the degree of invariance
across multiple waves of data simultaneously. In theory, it can identify and differentiate ‘‘true’’ treatment
responses from confounding effects, attribute responses directly to experimental treatments (nicotine admin-
istration and dosage), and permit the test of genetic effects on these responses. Thus, integration of structural
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modeling with association testing may improve statistical power when
well targeted hypotheses are postulated. To demonstrate the utility
and advantage of this approach, we conducted a pilot study to evalu-
ate the relationship between genetic risks of nicotine dependence and
the subjective responses resulting from nicotine administration. We
hypothesized that genetic risks of nicotine dependence contributed to
subjective responses, and that by integrating psychometric modeling
of psychological effects and dose effects we could improve statistical
power to detect this genetic association. In a lab setting, we recruited
208 non-smokers, and measured their psychological responses via
self-report by the Profile of Mood State (POMS)21, the Positive and
Negative Affect Scale (PANAS)22, and the Direct Effects of Nicotine
scale (DEN)23 after administration of each of a series of nicotine doses.
We used the 3 SNPs (rs16969968, rs588765 and rs578776) that were
shown to be associated independently with smoking quantity at the
CHRNA5-CHRNA3-CHRNB4 locus13 as an example. In this article,
we report the results of this pilot study.
Results
Our primary goals were to evaluate how nicotine administration
influenced subject’s mood and affect as measured by the POMS,
PANAS and DEN, and whether mood states and affect were influ-
enced by genetic risks of nicotine dependence using the established
markers from the CHRNA5-CHRNA3-CHRNB4 locus. Towards
these goals, we needed first to examine the latent factor structures
of the items of the instruments, and to evaluate whether the latent
measurement factor structures remained equivalent (i.e. statistically
invariant) after the administration of different nicotine doses using
measurement invariance (MI) testing procedures. A failure in theMI
testing would provide evidence that the latent factor(s) and the indi-
vidual differences they represent were not constructed equivalently
across the nicotine administrations, i.e., individual differences on the
latent factors were not calibrated in the same way across adminis-
trations, presumably due to differential item responses attributable to
the administration of different amounts of nicotine. Second, given
the factor structures, we could test the association between the factors
and genetic variants, and compare effects of the association across
different dosage.
Exploratory factor analyses of the POMS, PANAS and DEN.After
removing poorly responded to items, we conducted exploratory
factor analyses (EFA) for the POMS, PANAS and DEN item sets.
In the analyses of the POMS, 24 items were included. Specifically, we
conducted exploratory analyses for the 0 mg, 2 mg and 4 mg gum
sessions separately, extracting 3-, 4-, 5- and 6-factor solutions
respectively. A 5-factor solution fit the data adequately as judged
by the root mean square of the residuals (RMSR), root mean
square error of approximation (RMSEA), Tucker-Lewis Index
(TLI) and x2 test collectively (Table S1). For example, for the 0 mg
nicotine administration, compared to the 4-factor solution, the 5-
factor solution had better x2 P value (0.0028 vs. 1.0E-6), RMSEA
(0.045 vs. 0.057) and TLI (0.968 vs. 0.945), while the RMSR (0.03
vs. 0.03) was comparable. EFAs of the 2 and 4 mg of nicotine
administration showed the same results. Further examination
revealed that while the items consistently loaded onto the same
factors (configural invariance), some loadings displayed differences
Figure 1 | Configural latent variable measurement model for testing invariance across nicotine doses. The figure is shown using the PANAS Nervous
factor.
Table 1 | Summary of measurement invariance test of the POMS models
Model DF x2 D x2 D DF D x2 P CFI TLI RMSEA
POMS Positive Factors (‘‘Friendly’’, ‘‘Active’’ and ‘‘Clear Headed’’)
Configural model 879 1990.5 0.994 0.993 0.078
Metric Invariance 908 2043.9 10.5 29 0.9993 0.994 0.994 0.078
Scalar Invariance 1024 2229.3 397.1 116 ,2.2E-16 0.994 0.994 0.076
POMS Negative Factors (‘‘On Edge’’ and ‘‘Fatigued’’)
Configural model 218 242.9 0.999 0.999 0.024
Metric Invariance 236 297.8 32.2 18 0.0208 0.997 0.997 0.036
Scalar Invariance 288 577.6 444.5 52 ,2.2E-16 0.988 0.988 0.070
CFI: comparative fit index.
www.nature.com/scientificreports
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across the 3 nicotine dosages (Table S2). The 5-factor solution
included 3 positive and 2 negative factors. The first positive factor,
labeled Friendly, consisted of 7 items (Friendly, Considerate,
Efficient, Helpful, Cheerful, Good Natured and Trusting). The
second positive factor, labeled Active, consisted of the items of
Lively, Active, Energetic, Full of Pep and Vigorous. The third
positive factor, labeled Clear Headed, was contributed by 3 items
(Clear Headed, Unable to Concentrate (negative loading), and
Alert). The negative factors were called On Edge (Tense, On Edge,
Uneasy, Restless and Unable to Concentrate) and Fatigued (Worn
out, Fatigued and Sluggish). It appeared that the loadings for the
Friendly and Active factors changed significantly across the 3
nicotine gum doses while the Clear Headed, Uneasy and Fatigued
factors remained stable (Table S2). In the literature, there was a
report of a 5-factor structure of the POMS among smokers and
non-smokers24. Generally, the POMS items typically are reported
to have 6 distinct factors21,25. In our EFA using 6-factor solutions,
Sympathetic and Care Free had substantial loadings (,0.5) on the 6th
factors, but other item’s loadings on this sixth factor were below 0.2.
For this reason, they were excluded from further analyses.
Similar analyses were done for the PANAS. The EFA results poin-
ted to a 3-factor structure based on the RMRS, RMSEA, TLI and x2
test (Table S3). The 3-factor model, after the administration of 0 mg of
nicotine, had reasonable absolute fit (RMRS, 0.04) and comparative fit
(TLI, 0.075). While the 4-factor model had better absolute and com-
parative fits comparing to the 3-factor model, no indicator had a
reasonable factor loading (maximal l 5 0.42 for all indicators) on
the fourth factor. The models for the 2 and 4 mg of nicotine showed
the same pattern. Therefore, we decided on the 3-factor solution. The
first positive affect factor, labeled Inspired, included the following
items: Interested, Excited, Enthusiastic, Proud, Strong, Determined,
Inspired and Active. The second positive factor, Attentive, had strong
loadings for the items of Interested, Alert, Attentive and Active. Two
items, Interested and Active, had substantial cross loading on both
factors. The negative factor, Nervous, consisted of the items
Distressed, Nervous, Jittery, Afraid and Irritable. The loadings of indi-
vidual items were also consistent across the 3 nicotine doses (Table
S4). Typically, the PANAS shows a 2-factor structure, but in different
type of samples, latent structures of more than 2 factors have been
reported26. We did not find any report of structural analysis of PANAS
with smokers or with nicotine treatment.
The EFAs of theDEN suggested a 2-factor structure (Table S5). All
10 items had significant loadings (range from 0.23 , 0.78) on the
first factor. Two items, Dizzy and Light Headed, had significantly
higher loadings (0.82–0.94) on a second factor. The cross loadings
between the two factors were substantial (Table S6). When forcing a
single factor structure, the overall fit was worse than that of a two-
factor solution (for example, for the models after administration of
0 mg of nicotine, 1-factor model: RMRS 0.06, TLI 0.873, and x2 p
value 1.9E-14; 2-factor model: RMRS 0.03, TLI 0.964, and x2 p value
5.8E-3, Table S5). For this reason, we choose the 2-factor model in
the subsequent analyses. The 2 factors were Confused andDizzy. The
Confused factor had 7 items (Nauseous, Nervous, Sweaty, Headache,
Salivation, Heart Pound, and Confused), and the Dizzy factor had 3
items (Dizzy, Lite Headed and Weak).
Invariance tests for the POMS, PANAS andDENmodels.Based on
the results of EFA, confirmatory measurement models were
constructed for each of the 3 nicotine administrations for the
POMS, PANAS and DEN instruments. Since our sample size was
modest, to avoid over parameterization, models for the positive and
negative factors were modeled separately. In these common factor
models for each administration, correlations among the same item’s
residuals were allowed across the 3 nicotine doses since assessments
were obtained within relatively short time intervals leaving open the
possibility of memory carry over. Inter-factor correlations across the
doses and between different affect factors (since POMShad 3 positive
factors and 2 negative factors, and PANAS had 2 positive factors)
were also included. A path diagram of the general measurement
model is shown in Figure 1 using the PANAS Nervous factor as an
example.
Following general guidelines for MI testing, configural invariance
was first examined using the confirmatory factor analyses (CFA).
Based on the factor models derived from the EFAs, metric (factor
loadings) and scalar (thresholds/intercepts) invariance were
imposed across the 3 nicotine doses sequentially, and compared to
the saturated baselinemodel using RMSEA, TLI, BIC and x2 test. The
results of the MI tests for the POMS were summarized in Tables 1.
The overall model fits of the configural models for POMS were
reasonable (three positive factors, CFI 0.994, TLI 0.993, RMSEA
from 0.078; two negative factors, CFI 0.999, TLI 0.999, RMSEA
0.024). When the factor loadings were forced to be invariant across
the 3 nicotine doses, the change ofx2 was insignificant for the positive
factors (D x2 10.5, D DF 29, p 5 0.9993), and the change of x2 was
nominally significant (D x2 32.2, D DF 18, p 5 0.0208) for the
negative factors. Further constraining the thresholds led to highly
Table 2 | Summary of measurement invariance test of the PANAS models
Model DF x2 D x2 D DF D x2 P CFI TLI RMSEA
PANAS Positive Factors (Inspired and Attentive)
Configural model 364 707.9 0.997 0.997 0.068
Metric Invariance 388 832.5 57.9 24 1.24E-04 0.996 0.996 0.075
Scalar Invariance 468 904.7 175.6 80 3.98E-09 0.997 0.997 0.067
PANAS Negative Factor (Nervous)
Configural model 77 121.2 0.991 0.988 0.053
Metric Invariance 85 142.5 10.3 8 0.2458 0.989 0.986 0.057
Scalar Invariance 107 267.0 197.6 22 ,2.2E-16 0.969 0.969 0.085
Table 3 | Summary of measurement invariance test of the DEN models
Model DF AIC BIC x2 D x2 D DF D x2 P CFI TLI RMSEA
Configural model 409 7779.7 8267.0 1000.9 0.873 0.846 0.083
Metric Invariance 428 7777.6 8201.4 1036.7 26.8 13.5 0.0168 0.869 0.849 0.083
Scalar Invariance 444 7845.2 8215.7 1136.4 99.1 16.7 9.97E-14 0.851 0.834 0.087
AIC: Akaiki information criterion.
www.nature.com/scientificreports
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significant misfits for both positive and negative factors (positive
factors, D x2 397.1, D DF 116, p , 2.2E-16; negative factors, D x2
444.5, DDF 52, p, 2.2E-16). The overall fit indices were reasonable
(CFI 0.988–0.999, TLI 0.988–0.999, RMSEA 0.024–0.078).
Similar results for the PANAS and DEN were observed (Tables 2
and 3). For the PANAS items, the positive factors model also failed
the metric invariance test (D x2 57.9, DDF 24, p5 1.24E-4). Overall,
the failure of MI tests in all instruments at the metric and/or scalar
levels indicated that nicotine administration resulted in differential
item functioning for the mood and affect factors measured by the
POMS, PANAS and DEN. In other words, we found evidence that
volunteers responded differentially to some of the items in these
instruments after administration of different doses of nicotine,
resulting in the change of factor structure of these instruments.
These results provided a solid foundation for testing the association
of these nicotine specific effects with genetic variants associated with
nicotine dependence.
The association of genetic risks of nicotine dependence and latent
factors. Having shown that nicotine administration was related to
differential influences on subjects’mood and affect, we proceeded to
test if known genetic risks to developing nicotine dependence could
predict variation in these psychological measures. We selected
3 SNPs from the CHRNA5-CHRNA3-CHRNB4 locus to test the
association between the latent factors identified in our item level
analyses and the genotypes of these SNPs. In these models, the
factor loadings and thresholds/intercepts of all items were held
invariant across the 3 nicotine doses (i.e., as in scalar invariance
test, Figure 2A), forcing the effects of nicotine administration to be
represented at the latent factors. Under these conditions, we
regressed the latent factors onto the SNP genotypes, testing
whether SNP genotypes could linearly predict variation in the
latent mood factors. The results were summarized in Tables 4–6
for POMS, PANAS and DEN respectively. Regression results
suggested that the positive factors and negative factors had
different patterns. For the POMS positive factors, the Active factor
demonstrated nominally significant associationwith rs16969968, the
most significant finding at the CHRNA5-CHRNA3-CHRNB4 locus.
For the negative factors, most of them showed an association with
genotypes, although the strength of association was modest. SNP
rs588765 was associated with 4 of the 5 negative factors identified
in this study. Rs16969968 had association with 3 of the 5 factors.
These results indicated that genetic markers associated with nicotine
dependence predicted variations in negative mood and affect in
current non-smokers, the cohort used in this study. To visualize
the results, we computed the Nervous factor scores for the PANAS
dataset and plotted them against the genotypes of rs16969968
(Figure 2B). A similar plot was made for the DEN Confused factor
and rs588765 (Figure 2C). Of note, subjects carrying the risk alleles
(the A allele of rs16969968 and the C allele of rs588765) had lower
negative factor scores, indicating that these subjects tended to be less
negative on nicotine ingestion as compared to subjects not carrying
the risk alleles.
In these analyses, we tested the association of 3 SNPs with the
latent factors identified in ourmeasurementmodels across 3 nicotine
doses. The factors from the POMS, PANAS and DEN measured
different aspects of mood and affect, but they were not independent.
For example, the correlation between the factors varied from 0.3 to
0.9 for the DEN. The effects of nicotine on these factors were most
likely accumulative, i.e. the effects observed at 4 mgwere the sumof 2
and 4 mg of nicotine, because it took 30–45 min to reach maximal
plasma nicotine concentration after gum administration27,28. How to
correct for multiple testing was an important issue in evaluating the
significance of these tests. If we combined all positive and negative
factors in each instrument, and considered the 3 SNPs independent,
Figure 2 | Measurement model based association testing between SNP
genotypes and the means of latent factors. (A). The invariant base model
used in the testing. (B). The association between rs16969968 genotypes and
the scores of the PANAS Nervous factor. (C). The association between
rs588765 genotypes and the scores of the DEN Confused factor.
www.nature.com/scientificreports
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we needed to correct for 15 tests (2 positive factors and 3 negative
factors, for 3 SNPs). Under these conditions, rs588765 was assoc-
iated with DEN factors (Confused at 4 mg, p5 0.0003 and Dizzy at
0 mg, p 5 0.001). rs588765 and rs16969968 showed a trend for the
PANASNervous at 4 mg (p5 0.006 and 0.007 respectively). None of
the positive factors survived this correction.
To evaluate how nicotine dose influenced the mood and affective
states of volunteers, we conducted post hoc analyses for the DEN
factors that showed significant association with genotypes. In these
analyses, we compared the fit indices between two models: the SNP
model, with scalar invariance and SNP as exogenous predictor
(Figure 2A), and a constrained SNP model, which added constraints
on the regression coefficients of SNP prediction by setting paths a, b,
and c in Figure 2A to be invariant. The results were summarized in
Table 7. When the regression coefficients were forced to be equal
across the 3 nicotine doses, it caused significant misfit of the con-
strained model for SNP rs588765, the marker showing significant
association with the factors in this study. These results implied that
the regression coefficients (effect sizes) for rs588765 on DEN factors
were statistically different across the nicotine doses. Since the coeffi-
cients increased from 0 mg to 4 mg (Table 6), it could be interpreted
that the change of effect sizes was proportional to the amount of
nicotine administered.
Discussion
In this study, current non-smokers were recruited to examine the
effects of nicotine administration on their responses to the POMS,
PANAS and DEN instruments. Our objectives were to evaluate
whether previously identified genetic risks for nicotine dependence
(i.e., SNPs at the CHRNA5 locus) predicted variation of self-reported
subjective states using psychometric analyses with structural equa-
tion modeling. We performed exploratory and confirmatory factor
analyses to determine the factor structures of these instruments.
Based on these structures, we carried out MI testing to evaluate if
the administration of increasing levels of nicotine had an impact on
the structures. We further tested whether known genetic variants
were associated with these affective factors. The main findings of
our study were two-fold: 1) Using increasing nicotine doses and
repeated measures with standard instruments, we found that nic-
otine administration had significant differential impacts on the
mood measurement structures for both positive and negative affect
in current non-smokers, implying that nicotine dose had direct and
Table 4 | Association of POMS factors with SNPs*
Placebo (0 mg) Nicotine Gum (2 mg) Nicotine Gum (4 mg)
SNP Beta Se Z P Beta Se Z P Beta Se Z P
Friendly
rs16969968 0.065 0.110 0.593 0.5530 0.071 0.108 0.655 0.5120 0.065 0.114 0.569 0.5690
rs578776 0.126 0.110 1.146 0.2520 0.181 0.109 1.671 0.0950 0.155 0.111 1.397 0.1620
rs588765 20.023 0.102 20.22 0.8230 20.038 0.100 20.375 0.7080 20.039 0.103 20.380 0.7040
Active
rs16969968 0.189 0.110 1.720 0.0850 0.261 0.110 2.378 0.0170 0.228 0.115 1.977 0.0480
rs578776 0.095 0.110 0.866 0.3870 0.205 0.110 1.856 0.0630 0.155 0.118 1.320 0.1870
rs588765 0.011 0.102 0.110 0.9130 0.031 0.100 0.308 0.7580 0.049 0.105 0.466 0.6420
Clear Headed
rs16969968 20.106 0.125 20.85 0.3970 20.061 0.130 20.472 0.6370 0.002 0.126 0.019 0.9850
rs578776 0.082 0.130 0.636 0.5250 0.083 0.115 0.721 0.4710 0.115 0.127 0.907 0.3640
rs588765 20.111 0.116 20.957 0.3390 20.041 0.116 20.348 0.7270 0.004 0.121 0.031 0.9750
Uneasy
rs16969968 0.164 0.134 1.220 0.2220 0.166 0.123 1.349 0.1770 0.132 0.120 1.099 0.2720
rs578776 20.188 0.138 21.366 0.1720 20.017 0.126 20.134 0.8930 20.218 0.119 21.830 0.0670
rs588765 0.236 0.129 1.822 0.0690 0.109 0.126 0.861 0.3890 0.243 0.121 2.013 0.0440
Fatigued
rs16969968 0.132 0.128 1.032 0.3020 20.013 0.124 20.107 0.9150 20.045 0.123 20.368 0.7130
rs578776 0.090 0.121 0.750 0.4530 20.065 0.126 20.517 0.6050 20.109 0.126 20.865 0.3870
rs588765 0.056 0.114 0.491 0.6230 0.048 0.120 0.398 0.6900 0.037 0.115 0.321 0.7480
*P values # 0.05 were highlighted by bold fonts, and p values # 0.1 were highlighted by italic fonts and underscored.
Table 5 | Association of PANAS factors with SNPs
Placebo (0 mg) Nicotine Gum (2 mg) Nicotine Gum (4 mg)
SNP Beta Se Z P Beta Se Z P Beta Se Z P
Inspired
rs16969968 0.074 0.110 0.673 0.5010 0.154 0.111 1.389 0.1650 0.148 0.115 1.286 0.1990
rs578776 0.104 0.113 0.916 0.3600 0.151 0.112 1.340 0.1800 0.141 0.111 1.268 0.2050
rs588765 20.044 0.102 20.44 0.6630 20.005 0.104 20.04 0.9650 0.046 0.106 0.430 0.6670
Attentive
rs16969968 0.053 0.123 0.433 0.6650 0.108 0.115 0.939 0.3480 0.082 0.122 0.677 0.4980
rs578776 0.095 0.113 0.843 0.3990 0.130 0.106 1.218 0.2230 0.139 0.113 1.230 0.2190
rs588765 0.002 0.104 0.023 0.9820 20.001 0.104 20.013 0.9900 20.017 0.109 20.159 0.8740
Nervous
rs16969968 0.121 0.146 0.830 0.4060 0.406 0.169 2.394 0.0170 0.414 0.149 2.768 0.0060
rs578776 20.150 0.155 20.966 0.3340 0.082 0.14 0.587 0.5570 20.062 0.135 20.460 0.6460
rs588765 0.240 0.136 1.763 0.0780 0.218 0.148 1.471 0.1410 0.367 0.136 2.690 0.0070
www.nature.com/scientificreports
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measurable effects on items assessing mood and affect; and
2) Variation in mood and affect states under forced MI models were
predicted by previously identified genetic risk factors of nicotine
dependence, suggesting that the effects of nicotine on mood and
affect were linked to genetic risks of nicotine dependence.
Furthermore, post hoc analyses of rs588765 suggested that the effect
might be proportional to the amount of nicotine administered.
Our findings have important implications. Traditionally, genetic
studies of nicotine dependence use smokers (current smokers and/or
ex-smokers), and phenotype ascertainments focus on behavioral
outcomes (e.g., number and/or duration of cigarette use). The effects
of nicotine as a drug onmood and affect are rarely incorporated. Our
study is the first, to our knowledge, to provide direct evidence that
psychological effects of nicotine can be used for genetic studies of
nicotine dependence in current non-smokers.Whenwe designed the
study, we decided to use current non-smokers to avoid the complica-
tion of neuroadaptive changes associated with cigarette smoking29.
We reasoned that subjects with minimal exposure would be better to
measure the psychological effects of nicotine. Can we use these same
psychological effects from smokers for genetic studies of nicotine
dependence? A few reports in the literature suggest yes19,30,31.
However, we do not know whether the effects on smokers are more
or less informative compared to that of current non-smokers.
Therefore, a similar study in smokers would be of interest.
Interestingly, we were able to detect consistent association signals in
a sample of 208 subjects that might otherwise require a sample size
several times larger in a typical genetic association study. This indi-
cates that the integration of the drug effects of nicotine with psycho-
metric structural modeling can be a powerful approach in genetic
studies of nicotine dependence. In genetic studies, several factors influ-
ence the power. In addition to sample size, the reliability and accuracy
of phenotype measurements are one of the most important, but often
overlooked, factors to improve power for a given trait. In a typical
study of psychiatric trait, phenotypic data are normally based on self-
reports and the accuracy of these self-reports are far from satisfactory.
For this reason, researchers have used psychometric models to obtain
factor scores to serve as the phenotype32,33. In the studies of other
complex diseases such as cardiovascular diseases, researchers use bio-
logically relevant surrogates (i.e. endophenotypes)34 to improve power.
Specific to nicotine dependence study, cotinine, a major metabolite of
nicotine, has been used as a surrogate, and the study has demonstrated
tremendous improvement in statistical power11. In our study, we used
psychometric analyses of multiple waves of data to control for mea-
surement errors and confounding effects, achieving experiment-wide
significance for rs588765. In a study with 789 nicotine dependence
cases and 811 controls19, subjective responses similar to the DEN were
used as phenotypes. Although the study found associations between
the CHRNB3 gene and the ‘‘dizziness’’ phenotype, no associations
were found for any markers typed in the CHRNA5-CHRNA3-
CHRNB4 locus, including rs16969968 and rs578776, despite themuch
larger sample size. In contrast, with only 208 subjects, we found nom-
inal association between rs16969968 and the Dizzy factor. The gains in
power in our study, we believe, is partly due to the integration of
psychometric modeling of item level data for multiple waves of mea-
surement which effectively accounts for measurement errors and con-
founding effects. Another advantage of integration of psychometric
modeling with experimentally generated data is that it provides a
much stronger basis for interpreting the results. What the modeling
effects might be attributed to is more clearly defined and circum-
scribed, i.e. the controlled administration of nicotine in this study.
We also notice that while there are quantifiable differences for
both positive and negative effects across increasing doses of nicotine,
genetic associations are observed largely on the negative factors. This
may be due to the fact that our subjects are non-smokers, or because
negative affect factors have larger effect sizes. In the literature, there is
a suggestion that non-smokers (including both never smokers and
ex-smokers) react to smoking more negatively than smokers do24. In
this study, we did find that ever smokers had higher negative factor
scores than the never smokers, although the differences were not
statistically significant (data not shown). This greater negative affect
among the ever smokers toward nicotine administration may play a
role in their persistent abstinence.
This study has some limitations. Given the relatively small sample
size, while modest genetic effects are detected, most estimates do not
survive corrections formultiple comparisons. However, the observed
effects of SNPs are consistent across all doses of nicotine and for all
three subjective instruments; therefore, our modest associations are
more likely due to a small sample size rather than Type II error.
Nonetheless, further studies are needed to replicate and verify our
findings. The small sample size also prevents us from expanding to
Table 6 | Association of DEN factors with SNPs
Placebo (0 mg) Nicotine Gum (2 mg) Nicotine Gum (4 mg)
SNP Beta Se Z P Beta Se Z P Beta Se Z P
Confused
rs16969968 20.119 0.078 21.528 0.1270 20.158 0.082 21.941 0.0520 20.213 0.101 22.103 0.0350
rs578776 20.123 0.076 21.608 0.1080 20.134 0.092 21.446 0.1480 20.165 0.103 21.591 0.1120
rs588765 0.186 0.082 2.266 0.0230 0.203 0.082 2.472 0.0130 0.339 0.094 3.598 0.0003
Dizzy
rs16969968 20.198 0.079 22.498 0.0120 20.267 0.092 22.884 0.0040 20.118 0.105 21.121 0.2620
rs578776 20.096 0.080 21.204 0.2280 0.146 0.090 1.616 0.1060 20.019 0.089 20.212 0.8320
rs588765 0.247 0.075 3.276 0.0010 0.152 0.087 1.744 0.0810 0.183 0.090 2.035 0.0420
Table 7 | Post hoc analyses of nicotine dose on the DEN factors
SNP Model* Df x2 D x2 D DF D x2 P CFI TLI RMSEA
rs16969968 SNP 476 1275.7 0.828 0.811 0.090
Constrained SNP 480 1280.3 5.0 3.8 0.2650 0.828 0.812 0.090
rs578776 SNP 476 1291.3 0.826 0.808 0.091
Constrained SNP 480 1299.4 7.2 3.7 0.1056 0.825 0.808 0.091
rs588765 SNP 476 1279.5 0.828 0.810 0.090
Constrained SNP 480 1288.8 9.6 3.7 0.0396 0.827 0.810 0.090
*see text for full description of the models.
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more complex models to estimate the trajectory of the effects of
nicotine intake, and to test if the amount of change is proportional
to nicotine doses and if it is influenced by genetic risks of nicotine
dependence. These are of great interest for the research community,
and we hope to extend the study to address these questions.
In summary, in this study, we provide the first evidence linking
established genetic risk factors for nicotine dependence to mood
states and affect of non-smokers under controlled laboratory condi-
tions. These results demonstrate that the psychological effects of
nicotine as a drug can, and should be utilized in genetic studies of
smoking addiction and nicotine dependence. Study designs incorp-
orating these effects may bemore powerful than typical studies using
only smoking behaviors as phenotypes.
Methods
Subjects. Non-smokers of European ancestry between the ages of 18 and 50 years old
were recruited to participate in the study. We defined non-smokers as those individuals
who reported not smoking in the last 3 months and also smoking less than 100 cigarettes
during their lifetime. The cutoff of 100 cigarettes smoked in one’s lifetime is commonly
used to differentiate between ‘‘smokers’’ and ‘‘nonsmokers’’35,36. Current smoking status
was verified by breath carbon monoxide (CO) level (7 ppm or lower, BreathCO;
Vitalograph, Lenexa, KS), and by urine cotinine concentration (2 ng/mL or less).
Individuals were excluded if they reported a history of chronic health problems or
psychiatric conditions, were pregnant or breastfeeding, or had other major medical
conditions. The total number of subjects included for the study was 208, with an average
age of 26 years (standard error, se 0.49) and average years of education of 15.5 (se 0.14).
One hundred and eight were females (52.7%), and 102 (49.2%) reported having smoked
some cigarettes (i.e. these subjects smoked some cigarettes in their lifetime, but they did
not smoke in the last 3 months and the total number of cigarettes smoked was less than
100 cigarettes). The study was reviewed and approved by the IRB of Virginia Common-
wealth University. All subjects provided informed consent to participate in this study. The
experiments were conducted in accordance with procedures approved by the IRB.
Lab procedures. After providing informed consent, all volunteers participated in a
single laboratory session that included the administration of three doses of nicotine
gum in ascending dose order (0, 2, and 4 mg) and measurement of self-reported
mood and affect responses. Upon arrival to the laboratory, subjects were connected to
a physiological monitor (Model 507E, Criticare Systems) for continuous recording of
heart rate and blood pressure. Baseline self-report ratings using the POMS, PANAS
and DEN were also obtained. Participants were then administered the first piece of
nicotine gum (0 mg) and instructed to follow a computer-guided pacer to chew the
gum for 15 minutes37,38. Immediately after the gum was discarded, participants again
were asked to respond to the subjective questionnaire items. This same procedure
(15 minute standardized gum chewing period followed by subjective questionnaires)
was repeated for the 2 and 4 mg doses of nicotine gum, with 45 minutes in between
each administration. Blood samples were drawn prior to the first gum administration
for genotype analyses.
Outcome measures. We used the POMS, PANAS and DEN questionnaires to
evaluate the effects of nicotine administration on mood and affect. In this study, we
used POMS, a 65-item, single-word questions to assess each subject’s current mood
states21. For each question, a 5-level Likert type response format was used to record
the level of his/her affect at the time. The PANAS is a 20-item single-word
questionnaire designed to obtain positive and negative affect responses using a 5-level
response format22. The DEN is a 10-item single-word instrument tapping more
physiologically based aspects of nicotine effects (e.g., ‘‘dizzy’’)23. Participants
indicated their response to each item on a computerized scale ranging from 0 to 100
(whole numbers) using the computer pointer.
DNA extraction and genotyping.DNAs were extracted from blood samples using a
kit (Qiagen, QiaAmp DNA Blood Midi kit, Valencia, CA 91355) and manufacture
provided protocol. After the extraction, DNA samples were quantified and stored at
280uC. Genotypes for the subjects for rs16969968, rs588765 and rs578776 were
obtained using the TaqMan method39. The genotype and allele frequencies of the 3
markers were in Hardy-Weinberg equilibrium.
Data analyses. The POMS and PANAS items, and SNP genotype data were modeled
as ordered categorical (ordinal) variables. For the POMS and PANAS, items that
showed limited variability with more than 90% of subjects using only one of the
response categories were dropped from further analyses. Twenty four items of the
POMS and 15 items of the PANASwere retained and included in this analysis. For the
10 DEN items, a log 10 transformation was performed in an attempt to normalize
their distributions. All 10 items were included in the analyses. First, exploratory item
factor analyses were conducted for the POMS, PANAS andDEN item sets using the R
packages PSYCH and POLYCORwith oblimin rotation to determine the appropriate
dimensionality of the latent structures of each set of items. Second, measurement
invariance (MI) testing of the POMS, PANAS and DEN structures were performed
with the R packages LAVAAN40 and SemTools. MI testing was carried out to evaluate
if the affect factor measurement structures remained invariant across the different
nicotine gum administrations. Third, the associations of SNPs with the psychological
latent factors were tested within models where the loadings and thresholds/intercepts
of the indicators of each latent factor were constrained to be equal across the 3
nicotine administrations. This approach tests whether changes in factor scores are
confoundedwith any differential item functioning thatmay be present. Therefore, the
tests of association of the SNPs with the psychological factors provide estimates of
unambiguous effects indicating whether the genetic risk factors (i.e., SNPs) predict
variation and changes in psychological status in the context of the effects of different
doses of nicotine administration.
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